Chemo-Free hope: new pill combo targets Hard-to-Treat breast cancer

NCT ID NCT07716046

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether adding a new oral drug called fulvestaciclib to standard anti-HER2 and hormone therapy can help people with HR+/HER2+ advanced breast cancer live longer without their disease getting worse. Some participants receive the combo after initial chemotherapy, while others get it as a first-line treatment without any chemo. The goal is to find a more effective and less toxic option for this type of breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of fulvestaciclib (an oral CDK4/6 inhibitor), trastuzumab, pertuzumab, and an endocrine therapy (fulvestrant, letrozole, or anastrozole)
What this could lead to
If successful, this could offer a chemotherapy-free option for people with HR+/HER2+ advanced breast cancer, potentially delaying disease progression and reducing side effects.
What could go wrong
This is a phase II trial, so the results are preliminary. The combination may not improve outcomes over standard therapy, and side effects from the drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.